Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice

Acta Haematologica

Volumn 113, Issue 3, 2005, Pages 163-174

  Sasu, Barbra J ^a   Hartley, Cynthia ^a   Schultz, Henry ^a   McElroy, Patricia ^a   Khaja, Raheemuddin ^a   Elliott, Steven ^a   Egrie, Joan C ^a   Browne, Jeffrey K ^a   Begley, C Glenn ^a   Molineux, Graham ^a  

^a AMGEN INC   (United States)

Author keywords

Aranesp ; Darbepoetin alfa; Epoetin alfa; Erythropoietic units; Hemoglobin

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STANDARD;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; MICE; REFERENCE STANDARDS;

EID: 20844456080     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084446     Document Type: Article

References (30)

1. Maxwell AP, Lappin TR, Johnston CF, Bridges JM, McGeown MG: Erythropoietin production in kidney tubular cells. Br J Haematol 1990;74:535-539.
2. Jelkmann W: Erythropoietin: Structure, control of production, and function. Physiol Rev 1992;72:449-489.
3. Pugh CW, Tan CC, Jones RW, Ratcliffe PJ: Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc Natl Acad Sci USA 1991;88:10553-10557.
4. 2-supply to the kidneys and the production of erythropoietin. Respir Physiol 1989;77:111-117.
5. Krantz SB: Erythropoietin. Blood 1991;77: 419-434.
6. Adamson JW, Eschbach JW: Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 1990;41:349-360.
7. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA: Darbepoetin alfa has a longer serum half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-299.
8. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-421.
9. Catlin DH, Breidbach A, Elliott S, Glaspy J: Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 2002;48:2057-2059.
10. Goldwasser E: Erythropoietin - A somewhat personal history. Perspect Biol Med 1996;40: 18-32.
11. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7584.
12. Storring PL, Gaines Das RE: The International Standard for Recombinant DNA-derived Erythropoietin: Collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 1992;134:459-484.
13. Johnson DL, Farrell FX, Barbone FP, Mcmahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK: Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997;4:939-950.
14. SunBio: EPO conjugates. http://www sunbio co kr/sunbio/eng- sunbio4htm#PEG-EPO, 2002.
15. Burg J, Hilger B, Josel H: Erythropoietin conjugates. Official Gazette of the United States Patent & Trademark Office Patents [e-file] 1254:gov/web.
16. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Wilken J, Tang J, Levy JJ, Miranda LP, Crnogorac MM, Kalbag S, Botti P, Schindler-Horvat J, Savatski L, Adamson JW, Kung A, Kent SB, Bradbume JA: Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003;299:884-887.
17. Malik F, Brew J, Maidment SA, Delgado C, Francis GE: PEG-modified erythropoietin with improved efficacy. Exp Hematol 2000;28: 106.
18. Cotes PM, Bangham DR: Bio-assay of erythropoietin in mice made polycythaemic by exposure to air at a reduced pressure. Nature 1961; 191:1065-1067.
19. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Lawrence Erlbaum, 1988.
20. Scott SD: Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies. Pharmacotherapy 2002;22:160-165.
21. Walker R: Aranesp (darbepoetin alfa) administered at a reduced frequency of once every 3 weeks (q3w) and once every four weeks (q4w) maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis. National Kidney Foundation Clinical Nephrology Meeting, Spring 2002, Chicago, 2002.
22. Walker R: Aranesp (darbepoetin alfa) administered at a reduced frequency of once every 4 weeks (q4w) maintains hemoglobin levels in patients with chronic kidney disease (CKD) receiving dialysis. National Kidney Foundation Clinical Nephrology Meeting, Spring 2002, Chicago, 2002.
23. Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034.
24. Kotasek D, Berg R, Poulsen E, Colowick A: Randomized, double-blind, placebo controlled, phase I/II dose finding study of Aranesp™ administered once every three weeks in solid tumor patients. Blood 2000;96:294a-295a.
25. Harris D, Collins J, Disney A, Hawley C, Irish A, Kerr P, Makris A, Lynn K, Pollock C, Roger S, Walker R: Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002;7:S173-S180.
26. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86.
27. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-118.
28. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94: 1211-1220.
29. Locatelli F, Del Vecchio L, Marai P: Clinical experience with darbepoetin-alfa (Aranesp). Contrib Nephrol 2002;137:403-407.
30. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.